Login to Your Account



Clinic Roundup


Wednesday, May 16, 2012
• Galectin Therapeutics Inc., of Newton, Mass., said the first patient was dosed in a Phase I/II trial testing GM-CT-01, its carbohydrate-based galectin inhibitor, in combination with a peptide vaccine furnished by the Ludwig Institute for Cancer Research in advanced metastatic melanoma. The primary endpoint is partial or complete response.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription